Poly (diallylamines)-based phosphate binders
AssigneeGenzyme Corporation
InventorsW. Harry Mandeville, III, Stephen Randall Holmes-Farley
Life of this patent
Estimating the term…
Loading patent…
AssigneeGenzyme Corporation
InventorsW. Harry Mandeville, III, Stephen Randall Holmes-Farley
Estimating the term…
The present invention relates to a method for lowering the serum phosphate level of a patient. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer characterized by a diallylamine monomer or repeat unit. The amino nitrogen atom of the diallylamine repeat unit can be substituted by one or two substituents independently selected from among substituted and unsubstituted, normal, branched and cyclic alkyl groups, and aryl groups. When the diallylamine repeat unit comprises an ammonium or quaternary ammonium group, the monomer will further comprise a suitable anion, such as a conjugate base of a pharmaceutically acceptable acid.
A method for lowering the serum phosphate level of a patient comprising administering to the patient a therapeutically effective amount of a polymer characterized by a substituted or unsubstituted diallylamine repeat unit.
A method of lowering the serum phosphate level of patient comprising administering to the patient a therapeutically effective amount of polymer comprising a first monomer of the general formula
Dependencies are inferred from the claim text.